Biotest Aktiengesellschaft Top Insiders
| BIESFDelisted Stock | USD 32.00 0.00 0.00% |
Biotest Aktiengesellscha employs about 2 K people. The company is managed by 9 executives with a total tenure of roughly 6 years, averaging almost 0.0 years of service per executive, having 218.56 employees per reported executive. Examination of Biotest Aktiengesellscha's management performance can provide insight into the company performance.
| Katrin Bernster Insider Head Organisation |
| Monika Buttkereit Executive Head of Investor Relations |
Biotest |
Biotest Aktiengesellscha Management Team Effectiveness
The company has return on total asset (ROA) of (0.0331) % which means that it has lost $0.0331 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1833) %, meaning that it generated substantial loss on money invested by shareholders. Biotest Aktiengesellscha's management efficiency ratios could be used to measure how well Biotest Aktiengesellscha manages its routine affairs as well as how well it operates its assets and liabilities.Biotest Aktiengesellscha Workforce Comparison
Biotest Aktiengesellschaft is rated second in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 72,847. Biotest Aktiengesellscha holds roughly 1,967 in number of employees claiming about 2.7% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of (0.14) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.12) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.12. Biotest Aktiengesellscha Notable Stakeholders
A Biotest Aktiengesellscha stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biotest Aktiengesellscha often face trade-offs trying to please all of them. Biotest Aktiengesellscha's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biotest Aktiengesellscha's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael Ramroth | CFO, Head of Fin.s and Central Services and Member of the Management Board | Profile | |
| Christina Erb | Head of Corporate Project Management, Head of Center of Excellence Intensive Care Medicine and VP of HR | Profile | |
| Katrin Bernster | Head Organisation | Profile | |
| Monika Buttkereit | Head of Investor Relations | Profile | |
| Dirk Schuck | Member Board | Profile | |
| Peter Janssen | COO Board | Profile | |
| Georg Flo | COO Management | Profile | |
| Peter Seith | Quality Operations Officer | Profile | |
| Jorg Schuttrumpf | Chief Board | Profile |
About Biotest Aktiengesellscha Management Performance
The success or failure of an entity such as Biotest Aktiengesellscha often depends on how effective the management is. Biotest Aktiengesellscha management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biotest management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biotest management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. As of January 4, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A. Biotest Ag operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1928 people.
Biotest Aktiengesellscha Workforce Analysis
Traditionally, organizations such as Biotest Aktiengesellscha use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biotest Aktiengesellscha within its industry.Biotest Aktiengesellscha Manpower Efficiency
Return on Biotest Aktiengesellscha Manpower
| Revenue Per Employee | 262.1K | |
| Revenue Per Executive | 57.3M | |
| Net Loss Per Employee | 32.2K | |
| Net Loss Per Executive | 7M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Biotest Pink Sheet
If you are still planning to invest in Biotest Aktiengesellscha check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biotest Aktiengesellscha's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |